Skip to content
    Seawolf Therapeutics: Series A funding, $100 million, Announced
    Market Intelligence

    Seawolf Therapeutics Emerges From Stealth With $100M Series A Led by Versant

    Robert OdhiamboFounder, FundverseNovember 17, 20263 min read
    Share:

    Seawolf Therapeutics said it has raised $100 million in a Series A led by Versant Ventures and announced a Sanofi collaboration with up to $1.2 billion in milestones.

    Seawolf Therapeutics announced on November 16, 2026 that it has emerged from stealth, having raised $100 million in a Series A financing led by Versant Ventures. The US biotechnology company develops DNA-based therapeutics using its proprietary delivery platform.
    The company also announced a multi-target collaboration and exclusive license with Sanofi, with up to $1.2 billion in milestones and tiered royalties. Seawolf said in a statement distributed by Business Wire that it had raised the money "to transform patient outcomes through the use of its proprietary DNA delivery platform."

    The round and who joined it

    Versant Ventures led the Series A. Other investors named by the company are MPM BioImpact, Novartis Venture Fund, Eli Lilly and Company, CRISPR Therapeutics AG, Sixty Degree Capital, Alexandria Venture Investments and Pathway to Cures. The company said the round included others as well.
    The capital is equity. Seawolf did not disclose in the material provided the valuation, the share of the round each investor took, or how the proceeds will be allocated across programs. The investor group mixes specialist venture firms with corporate venture arms and strategic backers, a combination that is common in biotechnology financings.

    What Seawolf does

    Seawolf is a privately held company developing LNP-based DNA delivery therapeutics. LNP refers to lipid nanoparticles, a delivery format. The company's technology is called the TRIDENT platform. The company has not, in the information provided, disclosed its clinical stage, target diseases or pipeline candidates.

    The Sanofi collaboration

    The collaboration with Sanofi covers multiple targets and includes an exclusive license. Seawolf said the arrangement carries up to $1.2 billion in milestones plus tiered royalties. Milestone payments depend on development and other events and are not paid upfront, so the headline figure is a ceiling rather than cash received. The upfront payment, if any, was not disclosed.

    Why it matters for founders and investors

    A stealth launch with a funded Series A and a partnership announced on the same day shows one way a platform company can present itself to the market: capital from specialist and strategic investors, plus a commercial validation point in the form of a pharmaceutical partner. It does not show that the technology will work clinically. One financing and one collaboration are early signals, and the evidence given does not say how the platform has performed in the clinic.
    For founders in capital-intensive sectors, the structure is worth noting. Equity from a lead investor and strategic backers sat alongside a licensing deal whose value is tied to milestones. Founders weighing how much to raise and from whom can look at why a smaller round can sometimes be better than a bigger one, and at the costs of raising capital beyond dilution.
    Building a raise around a lead investor and strategic partners starts with finding the right ones. Fundverse can help you identify and approach investors whose focus matches your sector and stage.

    What to watch next

    The open questions are the ones the announcement leaves unanswered: how the $100 million will be deployed, how the Sanofi milestones are structured, and when Seawolf expects to reach the clinic. For investors tracking biotechnology financings, the combination of a lead venture firm, several strategic investors and a large pharma partner will be the reference point against which later updates from the company are read.

    Frequently asked questions

    Share:

    Topics

    Seawolf Therapeutics
    Series A
    Versant Ventures
    biotech funding
    DNA delivery
    LNP
    Sanofi collaboration
    TRIDENT platform

    Raising or investing?

    Find the right people on the other side of the table, and run the round in one place.